Author: LLPadmin

Latest Patent Further Strengthens Intellectual Property Portfolio Covering Novel Platform for Precisely Controlling Core Cell Migration Mechanisms Decelerator Technology Has Key Potential Applications in Treatment of Cancer and Fibrosis and Serves as Key Complement to Company’s Cell Motility Accelerator Platform for Enhanced Tissue Repair New York, NY – MicroCures, a biopharmaceutical company developing novel therapeutics that harness the body’s innate regenerative

U.S. Department of Defense Researchers to Study Ability of siFi2 to Drive Axon Regeneration and Functional Recovery following Spinal Cord Injury New York, NY – MicroCures, a biopharmaceutical company developing novel therapeutics that harness the body’s innate regenerative mechanisms to accelerate tissue repair, today announced that it has entered into a material transfer agreement (MTA) with the Henry M. Jackson Foundation

$1 Million in Funding from the USAISR Supporting Collaborative Research Project  Pilot Animal Study Successfully Completed; Larger Preclinical Study Underway  New York, NY – MicroCures, a biopharmaceutical company developing novel therapeutics that harness the body’s innate regenerative mechanisms to accelerate tissue repair, today announced the advancement of its ongoing collaborative research project with the United States Army Institute of Surgical Research

New Japanese Patent Further Strengthens Intellectual Property Portfolio Covering Company’s Novel Platform for Precisely Controlling Core Cell Migration Mechanisms Decelerator Technology Serves as Key Complement to Company’s Cell Motility Accelerator Platform for Enhanced Tissue Repair New York, NY – MicroCures, a biopharmaceutical company developing novel therapeutics that harness the body’s innate regenerative mechanisms to accelerate tissue repair, today announced the issuance

Funding to Support Ongoing Advancement of siFi2, Lead Candidate from Company’s First-of-its-Kind Platform for Precisely Controlling Core Cell Migration Mechanisms New York, NY – MicroCures, a biopharmaceutical company developing novel therapeutics that harness the body’s innate regenerative mechanisms to accelerate tissue repair, today announced that it has been awarded a Phase 2 Small Business Innovation Research (SBIR) grant from the National